SARTANS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS: A DUEL BETWEEN TWO LEADERS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES

SARTANS AND ANGIOTENSIN CONVERTING ENZYME INHIBITORS: A DUEL BETWEEN TWO LEADERS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES

Topical issues of cardiovascular disease pharmacotherapy influencing function of the renin-angiotensin-aldosterone system are discussed. Efficacy and safety of two major cardiovascular drug classes, angiotensin converting enzyme inhibitors and sartans, are compared. Data from evidence base of the bo...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. A. Gyamdzhyan, M. L. Maksimov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-12-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	renin-angiotensin-aldosterone system sartans angiotensin converting enzyme inhibitors pharmacotherapy of cardiovascular diseases captopril enalapril ramipril losartan valsartan irbesartan endothelial function atherosclerosis
Online Access:	https://www.rpcardio.online/jour/article/view/644
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness of an angiotensin II receptor blocker losartan as monoand combined therapy in hypertensive patients with various levels of renin-angiotensin-aldosterone system activity
by: Sh. V. Akhadov, et al.
Published: (2011-02-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

The role of the classical renin–angiotensin system and angiotensin-converting enzyme 2/Ang(1–7)/Mas axis in pulmonary fibrosis
by: Changhui Lang, et al.
Published: (2025-07-01)

View on the problem of diabetic nephropathy in children and adolescents with type 1 diabetes mellitus: the role of renin-angiotensin-aldosterone system (literature review) (part 1)
by: K. V. Skobeleva, et al.
Published: (2021-06-01)

RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND REPLICATIVE CELLULAR SENESCENCE: THEIR INTERACTION DURING THE VASCULAR AGEING
by: V. S. Pykhtina, et al.
Published: (2015-09-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Prospects of using genetic testing to increase the effectiveness of antihypertensive therapy
by: N. V. Drobotya, et al.
Published: (2020-06-01)

Heart and pulmonary artery remodeling association with various levels of natriuretic peptides and renin-angiotensin-aldosterone system activation in patients with pulmonary hypertension of various etiology
by: Yu. A. Andreeva, et al.
Published: (2008-12-01)

Blood aldosterone level in various types of atrial fibrillation
by: N. T. Vatutin, et al.
Published: (2016-02-01)

Angiotensin Converting Enzyme Inhibitors: Interaction Issues in Patients with Glaucoma and Arterial Hypertension. Review
by: S. I. Makogon, et al.
Published: (2023-12-01)

EFFECTS OF VITAMIN D ON THE RENIN-ANGIOTENSIN SYSTEM
by: L. Pashova-Stoyanova, et al.
Published: (2019-09-01)

The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
by: O. K. Vikulova, et al.
Published: (2020-08-01)

Dynamics of renin-angiotensin-aldosteron system and lipid profile in hypertensive hypothyrosis patients during the process of thyroid function compensation
by: P. Kh. Dzhanashiya, et al.
Published: (2004-12-01)

The effect of the <i>M235T</i> polymorphism of the angiotensinogen gene on the office blood pressure during therapy with angiotensin II receptor blockers
by: E. V. Rebrova, et al.
Published: (2024-12-01)

EVOLUTION STAGES OF LOW RENIN HYPERTENSION
by: S. V. Akhadov, et al.
Published: (2016-01-01)

ANGIOTENSIN II RECEPTOR TYPE 1 EXPRESSION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS
by: I. S. Mykhailichenko
Published: (2016-04-01)

ENDOCRINE DISFUNCTION IN WOMEN WITH PRE-ECLAMPSIA AND ALIMENTARY OBESITY
by: A. N. Rymashevskii, et al.
Published: (2017-06-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Role of angiotensin-converting enzyme inhibitors in reducing cardiovascular and cerebral complications in chronic kidney disease: focus perindopril
by: I. T. Murkamilov
Published: (2021-01-01)

Association of angiotensinogen and angiotensin II receptor type I polymorphisms with biomarkers of carbohydrate and lipid metabolism in Dagestan residents with type 2 diabetes and hypertension
by: M. Z. Saidov, et al.
Published: (2021-11-01)

Direct renin inhibitor aliskiren in women with menopausal metabolic syndrome and arterial hypertension
by: Yu. V. Zhernakova, et al.
Published: (2011-08-01)

THE CAPABILITIES OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CLINICAL PRACTICE: FOCUS ON VASOPROTECTION
by: D. B. Nebieridze, et al.
Published: (2015-12-01)

THE GENDER FEATURES OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: V. I. Podzolkov, et al.
Published: (2016-01-01)

Mechanisms of renal damage in patients with new coronavirus infection (literature review)
by: E. V. Utkina, et al.
Published: (2023-08-01)

Diagnostic Value of Let‐7a‐5p in Essential Hypertension
by: Lan Wang, et al.
Published: (2025-03-01)

Neurohumoral activation in arterial hypertension pathogenesis among patients with hypoD and hyperthyrosis
by: P. Kh. Dzhanashiya, et al.
Published: (2005-10-01)

Evaluation of the Hepatotoxicity Induced by Captopril and Enalapril in Rat Liver: A Comparative Study
by: Mohammed Ibrahim, et al.
Published: (2023-12-01)

Differential involvement of hippocampal angiotensin 1 receptors in learning and memory processes in bulbectomized rats
by: Tashev E. Roman, et al.
Published: (2016-04-01)

Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients
by: E. van der Merwe, et al.
Published: (2011-11-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

SUPPRESSION OF RENIN-ANGIOTENSIN SYSTEM TO PREVENT COMPLICATIONS OF CARDIOVASCULAR DISEASES: CURRENT "ROLES" DISTRIBUTION FROM CLINICAL PHARMACOLOGIST’S POINT OF VIEW
by: S. R. Gilyarevskiy, et al.
Published: (2016-01-01)

RAMIPRIL IN THERAPY OF PATIENTS AFTER MYOCARDIAL INFARCTION
by: I. V. Szirov, et al.
Published: (2015-12-01)

Arterial hypertension in thyrotoxicosis: neuro3humoral regulation, hemodynamic and metabolic changes
by: P. Kh. Dzhanashija, et al.
Published: (2004-02-01)

The use of angiotensin-converting enzyme inhibitors in general medicine
by: M.L.I. Mashitisho
Published: (2012-08-01)

Efficacy of Shenkang Injection combined with renin-angiotensin-aldosterone system blockers in diabetic nephropathy: a systematic review and meta-analysis of randomized controlled trials
by: Xinyue Zhang, et al.
Published: (2025-12-01)

INFLUENCE OF THE POLYMORPHISM OF THE RENIN-ANGIOTENSIN SYSTEM GENES ON THE CARDIAC ARRHYTHMIAS IN CHILDREN WITH HYPERTROPHIC CARDIOMYOPATHY
by: N. A. Berezneva, et al.
Published: (2013-05-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

The renin-angiotensin system in healthy human platelets: expressed but inactive
by: François Panosetti, et al.
Published: (2025-12-01)

Research progress on neurohumoral mechanism and clinical significance of vasovagal syncope
by: LI Qiheng, XIE Yucai
Published: (2024-12-01)

Emergency care in a sudden individually significant blood pressure increase without clinically overt target organ damage: rationale for captopril use. Expert Council opinion
by: S. N. Tereshchenko, et al.
Published: (2020-03-01)